title: New immunosuppressants in BMT/GVHD.
authors.affiliation: Department of Hematology/Oncology, BMT Unit, Oberstein, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Basara
authors.forename: S
authors.initials: S
authors.lastname: Günzelmann
authors.forename: W
authors.initials: W
authors.lastname: Willenbacher
authors.forename: A A
authors.initials: AA
authors.lastname: Fauser
authors.forename: M G
authors.initials: MG
authors.lastname: Kiehl
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003587:Cytomegalovirus / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000503:physiopathology; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014775:Virus Activation
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D009173:Mycophenolic Acid